Robert Eckel
Endocrinology, Diabetes & Metabolism · Aurora, CONPI 1831289503
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 30.0% of the total. Reporting peaked in 2019 at $20,875 and has fallen 57.8% since, to $8,803 in 2025. Among endocrinology, diabetes & metabolism clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $791.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$20K
- Madrigal Pharmaceuticals$10K
- Janssen Scientific Affairs, LLC$9K
- Tolmar Pharmaceuticals, Inc.$8K
- Kowa Research Institute, Inc.$5K
- Amarin Pharma, Inc.$4K
- plus $10K from 14 others
Across 3 payments — averaging $655.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
What the payments were for
- Consulting fees$39,14960%
- Speaking & faculty fees$15,43223%
- Travel & lodging$7,09111%
- Food & beverage$4,0396%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 9 | $19,693 |
| Madrigal Pharmaceuticals | 8 | $9,999 |
| Janssen Scientific Affairs, LLC | 4 | $8,999 |
| Tolmar Pharmaceuticals, Inc. | 9 | $7,609 |
| Kowa Research Institute, Inc. | 11 | $4,823 |
| Amarin Pharma, Inc. | 2 | $4,290 |
| Novo Nordisk | 13 | $4,016 |
| Amgen | 2 | $3,076 |
| Lilly USA, LLC | 1 | $1,250 |
| Kowa Pharmaceuticals America, Inc. | 6 | $683 |
| Novartis | 5 | $402 |
| Esperion Therapeutics, Inc. | 2 | $227 |
| Boehringer Ingelheim | 3 | $134 |
| Regeneron | 1 | $123 |
| Corcept Therapeutics | 2 | $99 |
| Regeneron Healthcare Solutions, Inc. | 1 | $77 |
| Ionis Pharmaceuticals, Inc. | 1 | $62 |
| Merck | 1 | $62 |
| Astellas Pharma US Inc | 1 | $59 |
| AstraZeneca | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,711 in reported general payments places this provider in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Other endocrinology, diabetes & metabolism in Aurora
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Halis AkturkAurora$109K
- Marc Andre CornierAurora$62K
- Jane ReuschAurora$59K
- James FalkoAurora$45K
- Aaron MichelsAurora$37K
- Margaret WiermanAurora$36K
- Peter GottliebAurora$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.